HealthTree Logo
search more_vert
close
person Sign In / Create Account
The FDA Is Reviewing A New Treatment Option For Relapsed/Refractory AML
Posted: May 01, 2024
The FDA Is Reviewing A New Treatment Option For Relapsed/Refractory AML image

Syndax Pharmaceuticals recently announced that the FDA will prioritize the review of revumenib for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged (KMT2Ar) acute leukemia. We will know about the FDA's decision by September 26, 2024.

What Is Revumenib?

Revumenib is a small molecule inhibitor that targets a protein called menin. Menin plays a role in the growth and survival of leukemia cells. By blocking menin, revumenib aims to disrupt the cancerous process and lead to the death of leukemia cells.

Revumenib is primarily being investigated for the treatment of relapsed or refractory (R/R) acute leukemias. This means the leukemia has either returned after initial treatment (relapsed) or hasn't responded well to standard therapies (refractory). Specifically, clinical trials are focusing on:

  • KMT2A-rearranged (KMT2Ar) acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
  • NPM1-mutant (NPM1m) AML

It's considered a "first-in-class" menin inhibitor, meaning it's one of the first drugs developed to target this specific protein in leukemia treatment.

The AUGMENT-101 Trial

The data supporting the approval submission was released in December 2023) and came from a pivotal AUGMENT-101 trial (phase 2) designed to evaluate revumenib's safety, tolerability, and efficacy. This trial studied revumenib, administered orally, to treat relapsed and refractory AML patients who had received several previous treatments with unsuccessful results.

  • 63% responded to the treatment.
  • 70% of the patients who achieved a complete remission were MRD negative. 
  • 39% received a stem cell transplant.
  • 50% restarted revumenib for maintenance therapy post-transplant.

The study investigators shared

"Any time you have relapsed or refractory acute leukemia, the only cure is a transplant, but to do that, you have to have a response. We observed encouraging, durable, and meaningful responses, and many of these patients were able to proceed successfully to transplant. We have not seen this level of activity with any other available treatment in this advanced disease setting." Ibrahim Aldoss

Some of the most common side effects patients experienced while taking revumenib were diarrhea, vomiting, decreased appetite, fatigue, dysgeusia (which affects one's ability to taste), and anemia. Most side effects were easily controlled, and revumenib was well tolerated. 

Source:

Learn More About Revumenib

 

The author Lisa Foster

about the author
Lisa Foster

Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home. 

Get the latest thought leadership on Acute Myeloid Leukemia delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Acute Myeloid Leukemia Newsletter" for Acute Myeloid Leukemia news, life with Acute Myeloid Leukemia stories, Acute Myeloid Leukemia clinical trials, Acute Myeloid Leukemia 101 articles and events with Acute Myeloid Leukemia experts.

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Abbvie
Astellas Pharma
Servier

Follow Us

facebook instagram youtube